PMID- 26923347
OWN - NLM
STAT- MEDLINE
DCOM- 20170130
LR  - 20170130
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 15
IP  - 6
DP  - 2016 Jun
TI  - Safety and tolerability of pneumococcal vaccines in children.
PG  - 777-85
LID - 10.1517/14740338.2016.1160056 [doi]
AB  - INTRODUCTION: A number of pneumococcal vaccines have long been available and have 
      been used to reduce the medical, social, and economic problems associated with 
      Streptococcus pneumoniae-related diseases. AREAS COVERED: The main purpose of 
      this review was to analyze what has been, until recently, the established 
      doctrine regarding the safety and tolerability of pneumococcal vaccines that have 
      been used in the past and are currently being used in children. EXPERT OPINION: 
      Pneumococcal vaccines available on the market are all safe and are highly 
      recommended in clinical practice. In children, pneumococcal conjugate vaccines 
      (PCVs) are considered the preparations of choice because of their enhanced 
      immunogenicity and superior ability to impact nasopharyngeal carriage. All PCVs 
      are considered safe because the incidence of severe adverse events (AEs) is 
      marginal. Nonetheless, evidence has emerged from post-marketing surveillance 
      regarding the occurrence of very rare but significant potential AEs following PCV 
      administration. Therefore, post-marketing surveillance should be maintained to 
      confirm the existence of these AEs. Over the next few years, other pneumococcal 
      vaccines will be developed. When these new products are licensed and reach the 
      market, new technologies and innovative epidemiological methods will permit a 
      more rapid and more effective evaluation of AEs.
FAU - Esposito, Susanna
AU  - Esposito S
AD  - a Pediatric Highly Intensive Care Unit, Department of Pathophysiology and 
      Transplantation , Universita degli Studi di Milano Fondazione IRCCS Ca' Granda 
      Ospedale Maggiore Policlinico , Milan , Italy.
FAU - Principi, Nicola
AU  - Principi N
AD  - a Pediatric Highly Intensive Care Unit, Department of Pathophysiology and 
      Transplantation , Universita degli Studi di Milano Fondazione IRCCS Ca' Granda 
      Ospedale Maggiore Policlinico , Milan , Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160321
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Pneumococcal Vaccines)
RN  - 0 (Vaccines, Conjugate)
SB  - IM
MH  - Child
MH  - Humans
MH  - Pneumococcal Infections/*prevention & control
MH  - Pneumococcal Vaccines/administration & dosage/*adverse effects
MH  - Product Surveillance, Postmarketing
MH  - Streptococcus pneumoniae/isolation & purification
MH  - Vaccines, Conjugate/administration & dosage/*adverse effects
OTO - NOTNLM
OT  - 10-valent pneumococcal conjugate vaccine
OT  - 13-valent pneumococcal conjugate vaccine
OT  - 23-valent pneumococcal polysaccharide vaccine
OT  - 7-valent pneumococcal conjugate vaccine
OT  - adverse events
OT  - pneumococcal vaccines
EDAT- 2016/03/01 06:00
MHDA- 2017/01/31 06:00
CRDT- 2016/03/01 06:00
PHST- 2016/03/01 06:00 [entrez]
PHST- 2016/03/01 06:00 [pubmed]
PHST- 2017/01/31 06:00 [medline]
AID - 10.1517/14740338.2016.1160056 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2016 Jun;15(6):777-85. doi: 10.1517/14740338.2016.1160056. 
      Epub 2016 Mar 21.